PRM46 R … YOU AWARE HOW USEFUL IT IS? THE VALUE OF CORRELATION COEFFICIENTS IN META-ANALYSIS  by Al-Dakkak, I. et al.
tual equivalence to ‘hassled’. CONCLUSIONS: Though not always possible to
translate an English word exactly into the target language, a full translation and
linguistic validation process, including creation of a concept elaboration document
followed by an in-depth discussion at back-translation review stage, enables a
conceptually equivalent translation to be found. The concept elaboration docu-
ment should, where possible, be created in conjunction with the instrument de-
veloper.
PRM41
IS IT TIME TO ELIMINATE THE ICER? USING NET BENEFITS TO REPORT THE
RESULTS OF DETERMINISTIC COST-EFFECTIVENESS ANALYSES
O’Day K, McLaughlin T, Bramley T
Xcenda, LLC., Palm Harbor, FL, USA
BACKGROUND: Incremental cost-effectiveness ratios (ICERs) are used to report the
results of cost-effectiveness (CE) analyses and represent the cost per unit of effec-
tiveness of a more costly and more effective option. However, numerous concep-
tual and practical problems limit the usefulness of ICERs for decision making.
These problems include, but are not limited to, negative ICERs, one-way sensitivity
analyses, complexity of multiple comparator analyses, and statistical limitations
with ratios. The net benefits approach was developed to address the statistical
limitations of ICERs and is now an accepted methodology used in probabilistic
sensitivity analysis to estimate CE confidence intervals and plot acceptability
curves. However, despite the remaining challenges and limitations the use of ICERs
persists, raising the question: Is it time to eliminate the use of ICERs in the report-
ing of CE analyses? METHODS: We propose expanding the net benefit method to
present deterministic CE analysis results using a net monetary benefit (NMB) chart
or table. ANMB chart is plottedwith the x-axis representing theWTP threshold and
the y-axis representing the NMB. The NMB of each option is a line with the inter-
cept representing the cost and the slope representing the effectiveness across a
specified range of WTP values. The line with the greatest NMB at a given WTP
represents the most cost-effective option at that WTP. The vertical distance be-
tween two lines represents the incremental NMB. Dominance, extended domi-
nance, and the frontier are captured graphically and intuitively. Multiple compar-
ator analyses are simplified and one-way sensitivity analyses are enhanced due to
the elimination of negative ICERs. CONCLUSIONS: A net benefits approach pro-
vides a more intuitive, informative, and useful method to present CE results than
the use of ICERs. Moreover, it has the benefit of facilitating a uniform and consis-
tent approach to presenting the results of deterministic and probabilistic CE anal-
yses.
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VISUALLY EVALUATING THE MEASUREMENT COMPARABILITY BETWEEN
PAPER-BASED AND ALTERNATE VERSIONS OF ADMINISTRATION OF THE LUNG
FUNCTION QUESTIONNAIRE
Gilligan T1, Nelson L1, McLeod L1, Dalal AA2
1RTI Health Solutions, Research Triangle Park, NC, USA, 2GlaxoSmithKline, Durham, NC, USA
In randomized crossover designs, intraclass correlation coefficients (ICCs) are often
used to assess the concordance between scores on different administration ver-
sions of patient-reported outcome (PRO) measures. An ICC and its associated cri-
terion for “adequate” concordance enable analysts to simplify information and
provide researchers with a quick and easy way to interpret analysis output. This
strength of the ICC—its simplicity—may also be a weakness. Analysts may over-
look important information (e.g., biases, outliers) when ICCs are used as the pri-
mary method for assessing concordance. One way to avoid overlooking important
information is to include the evaluation of Bland-Altman plots when assessing
concordance. Bland-Altman plots allow one to visually determine whether two
measures produce similar scores, therefore, supplementing the concordance in-
formation gained from the ICC evaluation. ICCs and Bland-Altman plots comple-
ment each other’s strengths. ICCs provide an efficient and concise estimate to
determine the comparability of versions, while Bland-Altman plots provide a
greater level of detail that incorporates a broader view of the analyzed distribu-
tions. The use of the two methods together provides a more holistic view of con-
cordance. We present Bland-Altman plots and corresponding ICCs under a ran-
domized crossover-design, using the Lung Function Questionnaire, a PRO
instrument originally designed to be administered via paper, and later via three
alternate administration versions (Web, interactive voice response system, and
interview). We provide examples to illustrate instances in which ICCs and Bland-
Altman plots agree and disagree. GSK study number: ADC001HO.
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BIOSIMILARS: DEMONSTRATING SIMILARITY THROUGH EVIDENCE
Kleintjens J1, Dahal D1, Mai JC1, Doyle JJ2
1Quintiles, Hawthorne, NY, USA, 2Columbia University, New York, NY, USA
OBJECTIVES: The differences in the active substance of biosimilars compared to
their originator reference product can cause risks that are unique to biologics,
mainly: immunogenicity, long-term safety risks, and lack of efficacy. These risks
are unknown at the launch of a biosimilar and can lead to unexpected costs for
payers. The aim of this abstract is to describe a methodology for evaluating the
unknown risks of biosimilars. METHODS: A structured literature review revealed
that for many biologics, post-marketing observational studies have been set up to
identify long-term safety and efficacy outcomes. These studies are a useful source
of information to quantify the unknown risks of biosimilars and definemethods of
minimizing those risks. The information required is product- and population-spe-
cific. This information first includes potential safety issues such as immunogenic-
ity (all biologics), serious infections and autoimmune disorders (anti-TNFs, inter-
ferons), and increased mortality and cardiovascular events (epoetin). Second,
information is available on long-term benefits such as clinical outcomes that im-
prove overall survival (e.g. reduced recurrence of malignancies through interferon
use and reduced cardiovascular events through insulin use), reduction in health-
care resource utilization (epoetin, somatropin), and proportion of long-term re-
sponders (figrastim, anti-TNF, somatropin). Finally, observational data can be used
to optimize treatment regimens to achieve maximum treatment benefit (epoetin,
insulin, somatropin). All these data can be used in an economic evaluation where
the unknown risks for biosimilars are quantified through worst- and best-case
scenarios. CONCLUSIONS: Often, payers are attracted to biosimilars that have the
lowest acquisition costs. However, the risks of unknown information for these
biosimilars should be valued against the lower price of these drugs. Observational
data for the originator biologic product can be leveraged to quantify these risks.
This can help determine for which drugs and for which populations the unknown
risks outweigh the reduction in acquisition costs.
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OPTIMUM METHODS FOR PRO TRANSLATION AND LINGUISTIC VALIDATION
METHODOLOGY: ONE BACK TRANSLATION OR TWO?
Furtado T, Anderson H, Griffin A, Wild D
Oxford Outcomes Ltd., Oxford, UK
OBJECTIVES: The translation of PRO measures requires a rigorous procedure, in-
cluding dual forward translations, reconciliation, back translation and review, and
debriefing interviews. The relevance of including blinded back translations has
been widely discussed; however, there has been little discussion around back
translation methods. This research aims to gauge the importance of having two
back translations versus only one.METHODS: Past translation and linguistic vali-
dation projects employing the procedures outlined above were reviewed to com-
pare the methodology of using one back translation versus two. RESULTS: In the
dual-back projects, numerous instances were found in which only one back trans-
lator detected an issue. For example: 1. Simple mistranslations can be revealed by
one translator but not another; e.g. ‘activities at home’ was back translated verba-
tim by one back translator but as ‘household activities’ by another, revealing that
the translated term was too narrow and related only to chores; 2. Similarly, con-
textual mistranslations may become apparent in dual back translations. In one
ePRO script, ‘enter training module’ meant to click through to the next page. One
back translator wrote ‘enter’, while ‘insert’ in the second translation highlighted
that the wrong term had been used in this context; 3. Dual translations are also
useful for elucidating nuances in meaning. In Danish, the phrase ‘bad tempered’
became ‘lose my temper’ in one back translation, allowing the lead translator to
alter the ambiguous translation; 4. Dual meanings in the target language may also
be highlighted, for example in Gujarati ‘hospitalisations’ was correctly back trans-
lated by one translator, but the other translated it as ‘clinic’, showing an ambiguity
in the translation. CONCLUSIONS: The high proportion of issues highlighted by
only one back translator, show the importance of using two blinded back transla-
tors in the translation of PRO measures.
PRM45
PILOT TESTING TRANSLATIONS OF PRO MEASURES WITH SENSITIVE
POPULATIONS
Verjee-Lorenz A, Clayson D, Two R
PharmaQuest Ltd, Banbury, Oxfordshire, UK
The ISPOR Principles of Good Practice paper on the translation of patient-reported
outcome (PRO) measures includes cognitive debriefing as a key step in the trans-
lation process. Cognitive debriefing refers to the process of asking patients to de-
scribe to an interviewer what each question/instruction means to them in their
own words. This allows experienced project managers to then determine whether
the patient has correctly understood the conceptual meaning of the question/
instruction and therefore, by implication, whether the translation is accurate. De-
spite the FDA guidelines emphasising the importance of assessing the content
validity of PRO translations, cognitive debriefing is not always feasible or ethically
acceptable with certain patient groups. These groups include children, severely ill
patients and patients with mental health problems, for whom prolonged inter-
views could cause distress. In these circumstances, alternative methodologies
should be employed to establish whether the wording is suitable for the given
population. Evidence from working with such patients indicates that clinician re-
views, caregiver reviews and assessments of language complexity and suitability
are all useful alternative methods for establishing the acceptability of PRO trans-
lations for particular patient populations. Two examples include pilot testingmen-
tal health measures with clinicians as a substitute for patients experiencing acute
symptoms and pilot testing paediatric measures with health practitioners and
teachers working with children from the target age group. Cognitive debriefing is a
useful tool in the translation and linguistic validation of PROmeasures but a more
flexible approach is required to ensure that certain patients are not unduly dis-
tressed and burdened by the process.
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R . . . YOU AWARE HOW USEFUL IT IS? THE VALUE OF CORRELATION
COEFFICIENTS IN META-ANALYSIS
Al-Dakkak I, Patel S, Jen MH, von Maltzahn R
HERON Evidence Development Ltd, Luton, UK
Meta-analysis involves pooling effect sizes to combine results from studies at-
tempting to answer similar research questions. Typically, a commonmetric is used
to estimate associations between independent and dependent variables in pooled
studies. Nonetheless, studies vary considerably in their measurement of effect
sizes as well as the nature of studied variables. The calculation of an effect size r
allows the pooling of results that are reported in a variety of forms. In the presence
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of needed raw data, r can be computed from relative risks, odds ratios, t statistics,
F statistics, chi square statistics, standard normal deviate Z statistics, and beta
coefficients. In studies reporting p-values only, p-values can be converted to their
associated one-tailed standard normal deviate Z values to allow the calculation of
r. Before computed r’s can be combined, theymust be transformed using the Fisher
Z transformation in order to normalize their distribution. The weighted and un-
weighted Fisher Z transformed r’s are then converted back to r’s, and the weighted
and unweighted mean r’s are calculated. Confidence intervals around these esti-
mates show the degree to which they significantly differ from zero. For the un-
weighted mean r, the random effects confidence interval is usually preferred. Al-
though such confidence interval tends to be wider, it allows generalization to
studies other than those included in the sample. This methodology is demon-
strated using a dataset from a systematic review of published scientific literature.
The analysis shows how diversely-reported effects sizes can be converted and
combined to produce a summary r, which explains the association between spe-
cific determinant and outcome variables. Despite the value of correlation r inmeta-
analysis, it continues to be underused in the synthesis of scientific evidence.
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DEVELOPMENT OF LOCALLY ADAPTABLE VALUE ARGUMENTS: HOW CAN
BUCKETING OF COUNTRIES AT GLOBAL LEVEL HELP MANUFACTURERS?
Kirpekar S, Dummett H
Double Helix Consulting, London, UK
Data requirements from reimbursement authorities globally vary greatly due to
variation in importance of HTA and levels of acceptable complexity in submitted
economic evidence. Oftenmarket differences have been addressed by global phar-
maceutical companies by developing value arguments that address the most de-
veloped reimbursement systems, which then have to be adapted locally, often
resulting in the duplication of effort among local affiliates. Placing customer re-
quirements and informal preferences as the starting point of the development of
value arguments can increase efficiency and more specifically meet local HTA
needs. Methodologies that will support development of locally adaptable value
arguments – both value dossiers as well as health economic messages - requires
first of all the understanding of local payer needs. Countries requiring submission
of economic data can be classified on the basis of commonly required assessment
methods – budget impact analysis, cost effectiveness analysis and cost minimisa-
tion analysis, as well as the complexity accepted in both submitted clinical and
economic evidence. This complexity is in terms of level of complexity of data
requirements for Health Economic analysis, technical modelling approach, CE out-
come, local/international data preference, preference for comparator, preferred
time horizon amongst others. This can be used to divide these countries into buck-
ets with similar requirements. Globally developed value arguments can be devel-
oped and adapted to these buckets of countries and their needs. Basing value
arguments that are developed globally as mentioned, and then sent to local affili-
ates to adapt to the specific needs of their HTA system, on the preferences of
customers is expected to be crucial to ensure local success for reimbursement.
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DESIGN AND OPERATIONAL CONSIDERATIONS FOR PRAGMATIC CLINICAL
TRIALS TO SUPPORT HEOR EVALUATIONS
Ishak KJ1, Payne KA1, Schrammel M2, Caro JJ3
1United BioSource Corporation, Dorval, QC, Canada, 2United BioSource Corporation, Boulder, CO,
USA, 3United BioSource Corporation, Lexington, MA, USA
Unlike randomized controlled trials (RCTs), pragmatic clinical trials (PCTs) mea-
sure the relative benefits of competing treatments in actual practice, thus, are an
important pharmacoeconomic data source. Depending on the design features, tri-
als can vary in their degree of pragmatism. We undertook a brief review of the
literature to highlight specific PCT design considerations that optimize their utility
for health economic and outcomes research (HEOR) applications. A broad popula-
tion and active control groups, typical in PCTs, can help achieve generally repre-
sentative HEOR assessments and reduce reliance upon indirect comparisons. A
minimally restrictive protocol is needed to preserve a naturalistic focus, and for
reducing Hawthorne effects. Some control is required, however, tominimize study
biases. Randomization to initial treatment choice remains essential to avoid selec-
tion bias and confounding, but little control should be exerted on regimen changes
so that real-world prescribing patterns (switching, adding, and dropping) patterns
and patient behaviors (non-compliance, non-adherence) can be evaluated. In the
absence of blinding, ascertainment bias is also a risk; use of objectively measured
outcomes that may even be identifiable from medical charts can help. Capturing
clinical, resource utilization, safety, preference, and quality of life, outcomes can
lead to richer economic models, and better understanding of usual-care treatment
decisions. With a broad patient base, it is important to explore subgroup effects,
and to prioritize predictive analyses to identify response variation. Beyond a
thoughtful study design, key operational elements such as site selection, patient
recruitment and retention and ongoing study support are critical to PCT success.
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TRANSLATION AND LINGUISTIC VALIDATION – METHODOLOGICAL
IMPLICATIONS WHEN THE SOURCE MEASURE IS NOT ENGLISH
Clayson D1, Verjee-Lorenz A1, Two R1, Gerber R2, Beaudreuil J3
1PharmaQuest Ltd, Banbury, Oxfordshire, UK, 2Pfizer, Inc., New London, CT, USA, 3Université
Paris, Paris, France
Themajority of new PROmeasures are developed in English, with a small minority
developed in other languages. This poses the question of how to translate and
linguistically validate measures developed in languages other than English, when
the resources are simply not available for translating from the source language (e.g.
Hungarian) into the target language (e.g. Bengali). The URAM Scale assesses func-
tional performance of the hand in patients with Dupuytren’s Contracture. It was
developed in French and initially translated and linguistically validated into UK
English. Themethodology employed for this translationwas the reverse of a typical
English to French translation, whereby the French in-country investigator acted as
the project manager and an in-house project manager (qualified in French to Eng-
lish translation) acted as the in-country investigator. The translation into English
required consultation with the developer and two issues needed to be resolved in
order to develop the UK English version. One item required alternative wording as
it mentioned wash mitts, which are very rarely used in the UK, and for another
item, two verbs were required to convey the meaning of a single French verb. On
completion of the translation, the UK English version was then used as a source
version for the translation of the URAM Scale into several other European lan-
guages. During this process the translators were asked to work from the English
version but to also consider the relevance of the original Frenchwording for the two
items that required a change in English. For example, in countries where wash
mitts are used, this wording was retained instead of the new English wording
which used ‘flannel’. This experience highlights the importance of always consid-
ering the original development language when translating a measure using a gen-
erated English version as the source.
POSTER SESSION III:
DISEASE-SPECIFIC STUDIES
Cancer – Clinical Outcomes Studies
PCN1
CHEMOTHERAPY INDUCED NAUSEA AND VOMITING EVENT RATE AMONG
PATIENTS WITH CANCER TREATED WITH HIGHLY OR MODERATELY
EMETOGENIC CHEMOTHERAPY AND INITIATED ON PALONOSETRON VERSUS
OTHER 5-HT3-RECEPTOR ANTAGONIST ANTI-EMETIC PROPHYLAXIS IN A
HOSPITAL OUTPATIENT SETTING
Craver C1, Gayle J1, Balu S2, Buchner D2
1Premier, Inc., Charlotte, NC, USA, 2Eisai, Inc., Woodcliff Lake, NJ, USA
OBJECTIVES: To assess the rate of chemotherapy induced nausea and vomiting
(CINV) associatedwith palonosetron (a 5-hydroxy tryptamine3-receptor antagonist
[5-HT3-RA]) initiation versus other 5-HT3-RAs among patients with cancer on
highly [HEC] or moderately emetogenic chemotherapy (CT) [MEC] treatment in a
hospital outpatient setting.METHODS: Patients with a cancer diagnosis initiating
HEC or MEC and anti-emetic prophylaxis with palonosetron (Group 1) or other
5-HT3-RAs (Group 2) for the first time (index date) between 4/1/2007 – 3/31/2009
were identified from the Premier Perspective comparative database. Inclusion cri-
teria were patients aged 18 yearswith no evidence of nausea and vomiting or use
of HEC/MEC or anti-emetic medication in the 6-month pre-index date period, and
with 36-consecutive months of hospital data. Follow-up time was first of eight CT
cycles (a cycle was the unit of analysis) or six months post-index date. A negative
binomial distribution generalized linear multivariate regression model estimating
the CINV event rate on CT matched groups in the follow-up period was developed
after controlling for demographic and clinical variables. RESULTS: Of 6418 identi-
fied patients, 1522 (23.7%) initiated palonosetron. Group 1 patients comprised of
less African Americans (8.7% vs. 14.2%) and more Hispanics (5.7% vs. 4.5%);
p0.0001, more patients on HEC [50.5% vs. 41.5%; p0.0001], and more non-colon
gastrointestinal (10.3% vs. 6.3%) and breast cancer patients (19.5% vs. 16.8%);
p0.0001. In the follow-up period, the number of unadjusted CINV events between
the matched groups was lower for Group 1 [6957 vs. 7784; p0.054] patients. The
regressionmodel predicted a significant decrease (12.5%) in the CINV event rate per
CT cycle for Group 1 patients versus Group 2 patients; p0.0044. CONCLUSIONS: In
this retrospective hospital outpatient study, patientswith cancer treatedwithHEC/
MEC and initiated on palonosetron were more likely to experience a significantly
lower rate of CINV events versus those initiating other 5-HT3-RAs.
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SAFETY AND TREATMENT PATTERNS OF ANGIOGENESIS INHIBITORS IN
PATIENTSWITH METASTATIC RENAL CELL CARCINOMA (MRCC) IN THE UNITED
KINGDOM: PRELIMINARY RESULTS OF AN ONGOING CHARTS REVIEW STUDY
Hawkins R1, Wagstaff J2, Nathan P3, Sarda SP4, Vekeman F5, Korves C4, Dasgupta S2,
O’Mara S1, Fitton S1, Hayers J1, Tham C1, Wei R4, Luka A4, Neary MP6, Duh MS4
1University of Manchester, Manchester, UK, 2Singleton Hospital, Swansea, UK, 3Mount Vernon
Cancer Center, Northwood, Middlesex, UK, 4Analysis Group, Inc., Boston, MA, USA, 5Analysis
Group, Inc., Washington, DC, USA, 6GlaxoSmithKline, Collegeville, PA, USA
OBJECTIVES: This study evaluated the rates of and reasons for treatment modifi-
cations and occurrence of adverse events (AEs) among patients treated with anti-
angiogenic agents in UK clinical practice. METHODS: Data from medical records
were retrospectively reviewed at 3 large UK oncology centers for mRCC patients
who were 18 years and received sunitinib (N90) as first-line treatment from
January 1, 2005 to October 15, 2010. Proportions of patients with treatment modi-
fications (i.e.: discontinuation, interruption, or dose change) and reasons for mod-
ifications were determined. Time to treatment discontinuation and proportion of
patients with all grade and grade 3/4 AEs were also determined. Data on clinician
assessed response rates was collected. RESULTS: Ten percent of patients were
cytokine-pretreated. Average daily dose over initial cycle was 31.98 mg; 77.8% of
patients started treatment with recommended dosing of 50 mg QD 4/2. Among the
62 patients with available tumor response assessments, 35.5% had an objective
response (OR; complete or partial response). A total of 84.4% of patients experi-
enced AEs; 24.4% experienced grade 3/4 AEs. The most commonly reported all
grade AEs were diarrhea (35.6%), mucositis/stomatitis (34.4%), and fatigue (26.7%);
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